Chemotherapy Induced Peripheral Neuropathy Market Growth Opportunities and Forecast by 2028

Historic Data: 2019-2020 | Base Year: 2021 | Forecast Period: 2022-2028

Chemotherapy Induced Peripheral Neuropathy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class (Steroids, Antidepressants, Anti-Seizure, and Narcotics) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy)

Report Date : May 2022
Report Code : TIPRE00028941

Category : Life Sciences
Status : Published

Available Report Formats :
No. of Pages : 151

Analysis Strategic Insights Market Drivers Regional Insights Report Scope Recent Developments FAQs

[Research Report] The chemotherapy induced peripheral neuropathy market is projected to reach US$ 1,174.26 million by 2028 from US$ 813.48 million in 2021; it is expected to register a CAGR of 5.4% from 2021 to 2028.

Chemotherapy-induced peripheral neuropathy is one of the most frequent side effects caused by antineoplastic agents. Clinically, it is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, chemotherapy-induced peripheral neuropathy constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing it; moreover, the possibilities of treating this syndrome are limited.

Customize This Report To Suit Your Requirement
You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Chemotherapy Induced Peripheral Neuropathy Market: Strategic Insights

Get Top Key Market Trends of this report.
This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

The report offers insights and in-depth analysis of the chemotherapy induced peripheral neuropathy (CIPN) market emphasizing market trends, technological advancements, and market dynamics. It also provides the competitive landscape analysis of leading market players across the world. Furthermore, the report includes the impact of the COVID-19 pandemic on the chemotherapy induced peripheral neuropathy market across all the regions. The pandemic has created both a public health crisis and an economic crisis worldwide. The global market for chemotherapy induced peripheral neuropathy before the pandemic was constantly growing owing to regularity of cancer screening, consultations, and treatments. The first wave of COVID-19 disrupted the consultations, follow-ups, and screenings of oncological cases. Moreover, disruptions in clinical trials and drug supply to patients during the early stage of the COVID-19 pandemic impacted the most crucial areas of the chemotherapy induced peripheral neuropathy market. A shift in focus to the prompt treatment of COVID-19 led to negligence toward various other medical conditions. In addition, the decrease in the detection of cancer cases and chemotherapy sessions for treatment hampered the demand for chemotherapy induced peripheral neuropathy diagnoses and treatments.

Market Insights

Increasing Prevalence of Cancer Drives Chemotherapy Induced Peripheral Neuropathy Market Growth

Cancer is a leading cause of death worldwide. According to the World Health Organization (WHO), cancer was reported as the first leading cause of death in the people of age below 70 years in 183 countries and the fourth leading cause of death among the population of all ages in 123 countries worldwide in 2019. In addition, as per the data published by the WHO in March 2021, different cancer types caused ~10 million deaths in 2020.

World’s Most Prevalent Forms of Cancer, 2020

This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

The increasing prevalence of cancer has created a burden on healthcare systems across the world, along with bolstering the demand for chemotherapy. Chemotherapy-induced peripheral neuropathy is a common adverse effect of neurotoxic anticancer drugs, such as platinum-derivative drugs (cisplatin and oxaliplatin), spindle poisons [taxanes (paclitaxel and docetaxel), vinca alkaloids, vincristine, epothilones, and eribulin], bortezomib, and thalidomide. The high prevalence of chemotherapy-induced peripheral neuropathy raises concerns about cancer patients and survivors, and their healthcare providers, especially because there is no single effective way to prevent this condition.

In a study conducted by “The Journal of the International Association for the Study of Pain,” chemotherapy-induced peripheral neuropathy prevalence was reported at 68.1% (57.7–78.4 when measured in the first month after chemotherapy, 60.0% (36.4–81.6) in the third month, and 30.0% (6.4–53.5) in the sixth month or later. Thus, the growing incidence of chemotherapy-induced peripheral neuropathy with the increasing prevalence of cancer boosts the growth of the chemotherapy-induced peripheral neuropathy market.

Drug Class-Based Insights

Based on drug class, the chemotherapy induced peripheral neuropathy market is segmented into steroids, antidepressants, anti-seizure, and narcotics. In 2021, the steroids segment held the largest share of the market. The anti-seizure segment is expected to register the fastest CAGR of 6.2% during the forecast period.

Distribution Channel-Based Insights

Based on distribution channel, the chemotherapy induced peripheral neuropathy market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. In 2021, the hospital pharmacy segment held the largest share of the market. Further, the retail pharmacy segment is expected to report the highest CAGR of 5.9% during 2021–2028.

The chemotherapy induced peripheral neuropathy (CIPN) market players focus on adopting organic strategies such as product launch and expansion to expand their footprint and product portfolio worldwide, as well as to meet the growing demands.

Chemotherapy Induced Peripheral Neuropathy Market Report Scope

By Geography

Based on geography, the chemotherapy induced peripheral neuropathy market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Company Profiles

Regenacy Pharmaceuticals, Inc.
Asahi Kasei Pharma Corporation
Novaremed
Makscientific, Llc
Wex Pharmaceuticals Inc.
Sova Pharmaceuticals, Inc.
Kineta, Inc.
Aptinyx Inc.
Apexian Pharmaceuticals, Inc.
Winsantor, Inc.

Chemotherapy Induced Peripheral Neuropathy Report Scope

Report Attribute	Details
Market size in 2021	US$ 813.48 Million
Market Size by 2028	US$ 1,174.26 Million
Global CAGR (2021 - 2028)	5.4%
Historical Data	2019-2020
Forecast period	2022-2028
Segments Covered	By Drug Class Steroids Antidepressants Anti-Seizure Narcotics By Distribution Channel Retail Pharmacy Hospital Pharmacy Online Pharmacy
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	REGENACY PHARMACEUTICALS, INC ASAHI KASEI PHARMA CORPORATION NOVAREMED MAKSCIENTIFIC, LLC WEX PHARMACEUTICALS INC SOVA PHARMACEUTICALS, INC KINETA, INC. APTINYX INC. APEXIAN PHARMACEUTICALS, INC.

Frequently Asked Questions

Who are the major players in market the chemotherapy induced peripheral neuropathy market?

The chemotherapy induced peripheral neuropathy market majorly consists of the players such as Regenacy Pharmaceuticals, Inc, Asahi Kasei Pharma Corporation., Novaremed, Makscientific, Llc, Wex Pharmaceuticals Inc., Sova Pharmaceuticals, Inc., Kineta, Inc., Aptinyx Inc., Apexian Pharmaceuticals, Inc., and Winsantor, Inc. amongst others.

What is the chemotherapy induced peripheral neuropathy market?

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating this syndrome are very limited.

Which segment is dominating the chemotherapy induced peripheral neuropathy market?

The chemotherapy induced peripheral neuropathy market, by drug class, is bifurcated into steroids, antidepressants, anti-seizure medicines, and narcotics. In 2021, the steroids segment held the largest share of the market. The anti-seizure medicines segment of the chemotherapy induced peripheral neuropathy market is expected to witness growth in its demand at the fastest CAGR during the forecast period.

What are the driving factors for the chemotherapy induced peripheral neuropathy market across the country?

The factors that are driving and restraining factors that will affect the chemotherapy induced peripheral neuropathy market in the coming years. Major factors driving the market growth include the increasing prevalence of cancer and increasing preference for chemotherapy. Additionally, the growing clinical trials for chemotherapeutic drugs is likely to emerge as a significant future trend in the market during the forecast period. However, lack of consolidated guidelines for chemotherapy hamper the chemotherapy induced peripheral neuropathy market growth.

Research Manager

Mrinal Kerhalkar

Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

What are the Chemotherapy Induced Peripheral Neuropathy Market report deliverables?

Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
PEST and SWOT Analysis
Market Size Value / Volume - Global, Regional, Country
Industry and Competitive Landscape
Excel Dataset

Chemotherapy Induced Peripheral Neuropathy Market Report Snapshots

Our Top Trending Reports

Testimonials

I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.

DR CHIJIOKE ONYIA, MANAGING DIRECTOR, PineCrest Healthcare Ltd.

The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services

Yukihiko Adachi CEO, Deep Blue, LLC.

Reason to Buy

Informed Decision-Making
Understanding Market Dynamics
Competitive Analysis
Customer Insights
Market Forecasts
Risk Mitigation
Strategic Planning
Investment Justification
Identifying Emerging Markets
Enhancing Marketing Strategies
Boosting Operational Efficiency
Tracking Industry Innovations
Aligning with Regulatory Trends

Your Key Concerns Addressed - Question & Answer

Can I view a sample of the report before purchasing?

Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.

Is analyst support included with the purchase?

Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.

What are the next steps once I place an order?

Once your order is successfully placed, you will receive a confirmation email along with your invoice.

• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.

Can the report be tailored to suit my specific needs?

We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.

In what format is the report delivered?

The report is available in either PDF format or as an Excel dataset, depending on the license you choose.

The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.

How secure is the payment process on your platform?

Our payment process is fully secure and PCI-DSS compliant.

We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.

Do you provide special pricing for buying multiple reports?

Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.

Can I connect with your team to discuss the report before buying?

Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.

Will I get a billing invoice upon purchase?

Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.

Is there support available if I can’t access my report?

Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.